How to use Atara Biotherapeutics Inc. ATRA as a Forecasting Tool ...

Analysts are estimating that Atara Biotherapeutics will report an earnings per share (EPS) of $-1.93. Atara Biotherapeutics ...

Atara Biotherapeutics (ATRA) could be a solid addition to your ... estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of ...

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The 36-month beta value for ATRA is at 0.45. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.” The public float ...

The Reverse Stock Split will become effective at 12:01 ... June 05, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein ...

Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.” The public float for ATRA is 3.97M, and at present, short sellers hold a 16.10% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...